Wednesday, January 20, 2021 9:20:52 PM
Based upon retrospective clinical data suggesting that patients with TKI–naive, EGFR–mutant NSCLC may be more likely to respond to ICIs compared with patients with TKI–resistant disease, Lisberg et al conducted a phase II trial of pembrolizumab in patients who were TKI–naive with EGFR–mutant and PD-L1–positive (tumor proportion score ≥ 1%) metastatic NSCLC.11 The study was stopped early because of lack of efficacy among patients with confirmed EGFR mutations (ORR: 0%). Of note, two patients who went on to receive EGFR TKIs after pembrolizumab developed grade 3 transaminitis and grade 5 pneumonitis, respectively.
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200428/full/
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM